Press release - 27/03/2024 Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101 Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for the treatment of multiple myeloma to its lead candidate HDP-101. Heidelberg Pharma is investigating the candidate in a clinical Phase I/IIa study for the treatment of relapsed/refractory multiple myeloma (RRMM).https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-pharma-granted-orphan-drug-designation-fda-its-proprietary-atac-candidate-hdp-101
Press release - 16/05/2023 Mast cells have an important impact on the development of chronic myeloid leukemia Chronic myeloid leukemia (CML) is a type of blood cancer that arises from malignant changes in blood-forming cells of the bone marrow. It mainly occurs in older individuals and represents about 20 percent of all adult leukemia cases. A research team from the Institute of Molecular Medicine and Cell Research at the University of Freiburg has now demonstrated for the first time that mast cells play a crucial role in the development of CML.https://www.gesundheitsindustrie-bw.de/en/article/press-release/mast-cells-have-important-impact-development-chronic-myeloid-leukemia
Dossier - 09/02/2015 Chemical tools for biological applications https://www.gesundheitsindustrie-bw.de/en/article/dossier/chemical-tools-for-biological-applications
Press release - 09/02/2021 New rapid test to detect coronavirus antibodies developed An international research team involving the universities of Paraná and Tübingen has developed a rapid test that can reliably identify Covid-19 antibodies in the blood within minutes. As the researchers report in the journal ACS Sensors, the new process is based on a simple measuring principle making it easy to carry out without expensive instruments, and is therefore suitable for use at mobile testing centers or by laboratories.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-rapid-test-detect-coronavirus-antibodies-developed
Press release - 08/05/2023 CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK Initial Phase 1 part started with multivalent modified mRNA influenza vaccine candidates. Candidates developed in collaboration with GSK within broad infectious disease vaccine program encode for antigens covering four WHO-recommended flu strains.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-announces-dosing-first-participant-combined-phase-12-study-multivalent-modified-influenza-vaccine-candidates-developed-c
Press release - 18/11/2021 Overcoming resistance to treatment for breast, bowel, and pancreatic cancer As cancer progresses, the tumor cells continually change, ultimately resulting in a tumor consisting of a large number of different cell clones with different characteristics. This is referred to as "tumor heterogeneity". In many cases, the cancer cells become resistant to the treatments available.https://www.gesundheitsindustrie-bw.de/en/article/press-release/overcoming-resistance-treatment-breast-bowel-and-pancreatic-cancer
Press release - 19/10/2022 Apogenix’ Asunercept Demonstrates Efficacy in Phase II Trial for the Treatment of Hospitalized COVID-19 Patients Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that asunercept showed statistically significant benefits for hospitalized COVID-19 patients in the ASUNCTIS trial. The open-label multi-center phase II trial investigated efficacy and safety of asunercept in 435 patients with moderate to severe COVID-19 disease.https://www.gesundheitsindustrie-bw.de/en/article/press-release/apogenixs-asunercept-zeigt-wirksamkeit-phase-ii-studie-zur-behandlung-von-covid-19-patienten-im-krankenhaus
Press release - 24/02/2021 Disease progression in childhood cancer: Lengthening of telomeres promotes relapse Neuroblastoma can spread relentlessly or shrink spontaneously. Scientists from the Hopp Children’s Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ), the University of Heidelberg and the National Center for Tumor Diseases (NCT) Heidelberg have shown that some malignant neuroblastomas employ a trick to avoid cell death: they use a special mechanism to lengthen the telomeres at the end of their chromosomes. https://www.gesundheitsindustrie-bw.de/en/article/press-release/disease-progression-childhood-cancer-lengthening-telomeres-promotes-relapse
Press release - 15/11/2021 Using T cell to target malignant brain tumors Doctors and scientists from the German Cancer Research Center (DKFZ) and from Heidelberg University's Medical Faculty Mannheim have successfully tested a neoantigen-specific transgenic immune cell therapy for malignant brain tumors for the first time using an experimental model in mice.https://www.gesundheitsindustrie-bw.de/en/article/press-release/using-t-cell-target-malignant-brain-tumors
Press release - 23/06/2023 The molecular control centre of our protein factories Researchers from Konstanz and Zurich have deciphered a biochemical mechanism that ensures that newly formed proteins are processed correctly when they leave the cell's own protein factories. This solves a decade-old puzzle in protein sorting.https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-control-centre-our-protein-factories
Press release - 08/01/2024 Brain tumors in children: Cancer cells become less aggressive as they migrate within the tumor Certain brain tumors in small children contain cells that develop very similarly to normal brain cells and others that have already developed malignantly, depending on where they are located within the tumor. https://www.gesundheitsindustrie-bw.de/en/article/press-release/hirntumoren-bei-kindern-krebszellen-werden-auf-ihrer-wanderung-im-tumor-weniger-aggressiv
Dossier - 23/01/2012 The neurosciences Robots that move like ants, brain electrodes that alleviate symptoms of Parkinson’s, arm prostheses that can be controlled with pure thought power – over the last few years enormous progress has been made in the neurosciences and there has been an increasing shift from pure basic to applied research. There is a great deal of creativity in applied research in Baden-Württemberg. Nevertheless, basic research in the southwest of Germany has never…https://www.gesundheitsindustrie-bw.de/en/article/dossier/the-neurosciences
Press release - 29/11/2021 Tracking down resistant cancer cells In multiple myeloma, a cancer of the bone marrow, relapse almost always occurs after treatment. Initially, most patients respond well to therapy. However, as the disease progresses, resistant cancer cells spread in the bone marrow, with fatal consequences for the patients.https://www.gesundheitsindustrie-bw.de/en/article/press-release/tracking-down-resistant-cancer-cells
Press release - 01/03/2024 Using Data to Improve Understanding of Relationships between Proteins and Diseases Working with a new Emmy Noether Group, Dr. Pascal Schlosser is investigating how machine learning can aid in understanding the complex relationships between genes, proteins, and diseases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/using-data-improve-understanding-relationships-between-proteins-and-diseases
New method for analysing blood samples - 26/11/2020 Personalised therapy monitoring for malignant melanomas Immunotherapy has greatly improved the survival chances of patients with malignant melanoma. A study has now begun at the Department of Dermatology at the University Hospital of Tübingen to develop a way to monitor the course of treatment as effectively as possible. It involves personalised monitoring using liquid biopsies in addition to conventional PET/CT examinations. This analysis procedure of blood samples could enable closer monitoring of…https://www.gesundheitsindustrie-bw.de/en/article/news/personalised-therapy-monitoring-malignant-melanomas
Press release - 03/03/2021 New Baden-Württemberg network to reduce animal experiments A new network has been set up in Baden-Württemberg aimed at reducing animal experiments as well as further improving animal welfare. It combines new approaches and measures at the state’s biomedical research locations, which are expected to limit stress in laboratory animals and steadily reduce the number of animals used in research in line with the 3R principles of Replacement, Reduction, and Refinement.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-baden-wuerttemberg-network-reduce-animal-experiments
Press release - 30/09/2021 New microscopy technique makes deep in vivo brain imaging possible A pioneering technique developed by the Prevedel Group at EMBL allows neuroscientists to observe live neurons deep inside the brain – or any other cell hidden within an opaque tissue. The technique is based on two state-of-the-art microscopy methods, three-photon microscopy and adaptive optics. The paper reporting on this advancement was published on 30th September 2021 in Nature Methods.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-microscopy-technique-makes-deep-vivo-brain-imaging-possible
Press release - 28/09/2022 First successful trial for early detection of HPV-related cancer of the pharynx Screening trials for the early detection of rare diseases often fail due to insufficient predictive power of the results. For the rare HPV-related cancer of the pharynx, scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) now relied on the combined detection of antibodies against two different viral proteins in a proof-of concept trial.https://www.gesundheitsindustrie-bw.de/en/article/press-release/erste-erfolgreiche-studie-zur-frueherkennung-von-hpv-bedingtem-krebs-im-rachenraum
Press release - 11/01/2021 CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced the publication of preclinical data demonstrating the induction of robust antibody and T cell responses of its COVID-19 vaccine candidate, CVnCoV, in non-human primates. https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevacs-covid-19-vaccine-candidate-cvncov-demonstrated-efficient-protection-non-human-primates-during-sars-cov-2-challenge-infe
Press release - 14/12/2021 EU regulation approved: G-BA collaborates on European health technology assessment Today, the EU Parliament adopted the EU Regulation on Health Technology Assessment (HTA), which includes not only new medicines (including gene and cell therapies), but also medical devices.https://www.gesundheitsindustrie-bw.de/en/article/press-release/eu-regulation-approved-g-ba-collaborates-european-health-technology-assessment
Press release - 28/01/2022 New insights into predicting the efficacy of active ingredients in drug development Drugs consist of molecules developed in the drug laboratory that bind to their target, usually a protein, and thus exert their effect. The actual duration of binding of a drug molecule to its target protein varies depending on the drug. The lifetime of the drug-target complex can play a critical role in the efficacy of a drug, as a long residence time at the target can be crucial for the drug's action in some cases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-insights-predicting-efficacy-active-ingredients-drug-development
Press release - 31/01/2022 Cancer research learns from space travel Researchers use epigenetic factors to investigate the role of stress in the development of tumor diseases. Experts believe that stress plays a major role in the development of tumors. One occupational group, for example, that experiences extreme stress over a short period of time is astronauts.https://www.gesundheitsindustrie-bw.de/en/article/press-release/cancer-research-learns-space-travel
Press release - 17/05/2023 Playing hide and seek in the centromere Centromeres, the DNA sections often found at the center of the chromosomes, display enormous interspecies diversity, despite having the same vital role during cell division across almost the entire tree of life. An international team of researchers has discovered that the variation in centromere DNA regions can be strikingly large even within a single species. The findings, now published in the journal Nature, shed light on the molecular…https://www.gesundheitsindustrie-bw.de/en/article/press-release/playing-hide-and-seek-centromere
Press release - 29/11/2023 Tracing the Evolution of the Cerebellum Heidelberg scientists unveil genetic programmes controlling the development of cellular diversity in the cerebellum of humans and other mammals. The research results have now been published in the journal Nature.https://www.gesundheitsindustrie-bw.de/en/article/press-release/tracing-evolution-cerebellum
COVIC-19 clinical trial - 07/04/2022 Convalescent plasma for COVID-19 therapy: clinical trial should bring clarity Does it help to treat COVID-19 sufferers with antibodies from people who have recovered from the disease? It seems an obvious idea and has been tested thousands of times. However, there is not yet enough evidence to prove the clinical efficacy of treating COVID-19 patients with convalescent plasma. The transfusion physician Prof. Dr. Hubert Schrezenmeier from Ulm is planning to carry out a follow-up clinical trial to find the missing evidence.https://www.gesundheitsindustrie-bw.de/en/article/news/convalescent-plasma-covid-19-therapy-clinical-trial-should-bring-clarity
Press release - 11/01/2022 Obesity at a young age - a risk factor for early colorectal cancer The incidence of colorectal cancers in young adults is increasing. At the same time, the proportion of overweight and obese young people is also on the rise. Whether there is a connection between these two observations, however, was not known until now. Scientists at the DKFZ have now shown that the risk of early colorectal cancer is significantly increased in overweight young people compared to normal-weight peers.https://www.gesundheitsindustrie-bw.de/en/article/press-release/obesity-young-age-risk-factor-early-colorectal-cancer
Press release - 09/09/2022 Breaking down proteins: How starving cancer cells switch food sources Cancer cells often grow in environments that are low in nutrients, and they cope with this challenge by switching their metabolism to using proteins as alternative "food". Building on genetic screens, an international team of scientists could identify the protein LYSET as part of a pathway that allows cancer cells to make this switch. Their findings are now published in the journal Science.https://www.gesundheitsindustrie-bw.de/en/article/press-release/neu-identifiziertes-protein-ermoeglicht-krebszellen-auf-alternative-nahrungsquellen-auszuweichen
Neurosciences - 28/02/2024 Mesh microelectrode arrays: research with brain organoids on a new level How does the brain work? Brain organoids are derived from pluripotent stem cells and regarded as valuable model systems that can depict some aspects of neurological functioning. Dr. Peter Jones from NMI together with Dr. Thomas Rauen from the MPI for Molecular Biomedicine in Münster, has taken organoid research to a new level. His novel mesh microelectrode array (Mesh-MEA) greatly improves the growth and electrophysiological analysis of tissue.https://www.gesundheitsindustrie-bw.de/en/article/news/mesh-microelectrode-arrays-research-brain-organoids-new-level
Macrophages interacting with cytomegaloviruses - 22/02/2022 Cytomegaloviruses subvert macrophage identity Cytomegaloviruses are basically harmless. However, if they occur along with other pathogens, they can trigger serious diseases. They can manipulate our immune system and encourage resident defence cells to migrate. Researchers at the Centre for Chronic Immunodeficiency (CCI) at the Freiburg University Medical Centre have discovered which mechanisms underlie the behavioural changes in macrophages that make it easier for other pathogens to attack.https://www.gesundheitsindustrie-bw.de/en/article/news/cytomegaloviruses-subvert-macrophage-identity
Press release - 06/01/2023 CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced positive preliminary data from ongoing Phase 1 clinical programs in COVID-19 and seasonal flu, assessing both modified and unmodified mRNA technology. The tested vaccine candidates are being developed in collaboration with GSK.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-announces-positive-data-joint-covid-19-and-flu-mrna-vaccine-development-programs
Press release - 07/12/2021 Moderate immune response is more effective against leukemia The development of immunotherapies against blood cancer could be more successful if T cells are activated moderately rather than excessively. Scientists from the German Cancer Research Center have now been able to show this in mice: If the researchers blocked a cytokine that slows down the immune system, the T cells became exhausted and failed in the fight against leukemia.https://www.gesundheitsindustrie-bw.de/en/article/press-release/moderate-immune-response-more-effective-against-leukemia
Press release - 01/04/2022 FDA approval for targeted radioligand therapy for treatment of metastatic prostate cancer On March 23, 2022, the U.S. Food and Drug Administration (FDA) granted approval to the first targeted radioligand therapy against metastatic prostate cancer based on a joint patent of the German Cancer Research Center (DKFZ) and the University of Heidelberg. The agent significantly improves the chances of survival for those affected.https://www.gesundheitsindustrie-bw.de/en/article/press-release/fda-approval-targeted-radioligand-therapy-treatment-metastatic-prostate-cancer
Press release - 02/08/2023 Freiburg research team casts light on signal-dependent formation of mitochondria Known as the power plant of the cell, mitochondria are essential to human metabolism. Human mitochondria consist of 1,300 different proteins and two fatty biomembranes. The vast majority of mitochondrial proteins are produced with a cleavable transport signal and have to be actively transported into the mitochondria. https://www.gesundheitsindustrie-bw.de/en/article/press-release/freiburger-forschungsteam-klaert-signalabhaengige-bildung-von-mitochondrien-auf
Press release - 19/09/2023 Better distinguish chronic inflammation and cancer of the pancreas Current diagnostic methods do not always reliably distinguish between chronic inflammation of the pancreas and pancreatic cancer. About one third of all diagnoses are inconclusive. Scientists from the German Cancer Research (DKFZ) and from Heidelberg University Hospital (UKHD) therefore searched for molecular markers that could specify this diagnosis.https://www.gesundheitsindustrie-bw.de/en/article/press-release/chronische-entzuendung-und-krebs-der-bauchspeicheldruese-praeziser-unterscheiden
Dossier - 02/12/2013 RNA interference confidence is returning The 15-year history of RNA interference is not short on dramatic effects. It begins with the unexpected discovery and publication of the process of post-transcriptional gene silencing in 1998 for which the two Americans Andrew Fire and Craig Mello were awarded the Nobel Prize in Physiology or Medicine just eight years after their discovery. In 2001 Thomas Tuschl succeeded in switching off genes in human cells with small synthetic pieces of RNA…https://www.gesundheitsindustrie-bw.de/en/article/dossier/rna-interference-confidence-is-returning
Multiple sclerosis - 12/03/2020 Direct application of biopharmaceuticals through the nose into the brain There is currently no cure for multiple sclerosis, the most common neurological autoimmune disease in humans. Biopharmaceuticals that can delay the course of the disease or diminish its effects are often prevented from being fully effective by the blood-brain barrier. A European consortium led by the Fraunhofer IGB, Stuttgart is developing a new technology that can transport an innovative active ingredient directly to the central nervous system.https://www.gesundheitsindustrie-bw.de/en/article/news/Direct-application-of-biopharmaceuticals-through-the-nose-into-the-brain
Press release - 16/11/2021 Cystic fibrosis & COPD: Mucus reprograms immune cells and promotes airway inflammation Scientists of the Translational Lung Research Center Heidelberg (TLRC) and the German Cancer Research Center (DKFZ) have discovered a new link between excessive airway mucus and chronic airway inflammation that is characteristic of cystic fibrosis and chronic obstructive pulmonary disease (COPD). The researchers showed that mucus in the airways reprograms certain cells of the immune system.https://www.gesundheitsindustrie-bw.de/en/article/press-release/cystic-fibrosis-copd-mucus-reprograms-immune-cells-and-promotes-airway-inflammation
Press release - 24/10/2022 How tumors suppress the development of metastases Why do metastases often only appear after the original tumor has been surgically removed? Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim Medical Faculty of Heidelberg University have now published an explanation for this phenomenon. They were able to identify a messenger substance of the cancer cells that locally promotes the growth of the primary tumor.https://www.gesundheitsindustrie-bw.de/en/article/press-release/wie-tumoren-die-entstehung-von-metastasen-unterdruecken
Press release - 23/05/2023 B cells promote liver cancer with dangerous dual strategy Inflammatory fatty liver disease (NASH, non alcoholic steatohepatitis ) and the resulting liver cancer are driven by autoaggressive T cells. Scientists from the German Cancer Research Center (DKFZ) now show what ist behind this destructive behavior. In both mice and humans with NASH, they found increased numbers of activated B cells in the gastrointestinal tract.https://www.gesundheitsindustrie-bw.de/en/article/press-release/b-cells-promote-liver-cancer-dangerous-dual-strategy
Press release - 25/10/2023 Epigenetically acting drugs could support cancer immunotherapy Epigenetically active drugs enable the cell to read parts of the genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetically-acting-drugs-could-support-cancer-immunotherapy
Press release - 25/10/2023 Epigenetically acting drugs could support cancer immunotherapy Epigenetically active drugs enable the cell to read parts of the genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetisch-wirkende-medikamente-koennten-krebs-immuntherapie-unterstuetzen
Press release - 02/02/2024 Epigenetic status determines metastasis Scientists from the German Cancer Research Center (DKFZ) and Medical Faculty Mannheim of the Heidelberg University investigated in mice how spreading tumor cells behave at the site of metastasis: Some tumor cells immediately start to form metastases. Others leave the blood vessel and may then enter a long period of dormancy. What determines which path the cancer cells take is their epigenetic status. https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetischer-status-entscheidet-ueber-metastasierung
Affimed GmbH - 01/07/2020 "Innate cell engager" fighting against cancer In the fight against tumour cells, d Affimed GmbH from Heidelberg relies entirely on the weapons of the innate immune system. Affimed has developed special innate cell engagers, which are bispecific antibodies that recognise tumour cells and bring them together with natural killer cells and macrophages of the innate immune system, which then kill the tumour cells. Clinical trials using the AFM13 molecule are ongoing.https://www.gesundheitsindustrie-bw.de/en/article/news/innate-cell-engager-fighting-against-cancer
Press release - 24/03/2021 Vaccination against mutated protein tested in brain tumor patients for the first time Tumor vaccines can help the body fight cancer. Mutations in the tumor genome often lead to protein changes that are typical of cancer. A vaccine can alert the patients' immune system to these mutated proteins. For the first time, physicians and cancer researchers from Heidelberg and Mannheim have now carried out a clinical trial to test a mutation-specific vaccine against malignant brain tumors.https://www.gesundheitsindustrie-bw.de/en/article/press-release/vaccination-against-mutated-protein-tested-brain-tumor-patients-first-time
Press release - 15/07/2021 Mechanism for differentiation of specific immune cell types discovered Under certain conditions, our immune system can efficiently fight off infectious diseases and cancer. T cells, especially the gamma delta T cell type, play an important role in this. The issue is that this cell type is extremely infrequent in the human body. Researchers at the University Hospital Tübingen, the University of Heidelberg and the European Molecular Biology Laboratory (EMBL) have now succeeded in finding the cause for the formation of…https://www.gesundheitsindustrie-bw.de/en/article/press-release/mechanism-differentiation-specific-immune-cell-types-discovered
Press release - 10/01/2022 Algorithm identifies cancer drivers Genetic alterations that promote the development and spread of tumors are difficult to identify. This is especially true for mutations in the non-protein-coding regions of the genome, which include all important regulatory sequences. Scientists at the German Cancer Research Center have now published an algorithm that detects cancer drivers in both the protein-coding and non-coding regions of the genome.https://www.gesundheitsindustrie-bw.de/en/article/press-release/algorithm-identifies-cancer-drivers
Press release - 24/01/2023 What keeps the immune defense in brain tumors functional Cancer immunotherapies often fail because the immune cells are paralysed by immunosuppressive conditions in the tumor. Scientists from Heidelberg, Mannheim and Tel Aviv have now shown on tissue samples from patients as well as on tumor models in mice that the functionality of the immune defence depends decisively on certain helper cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/was-die-abwehrzellen-hirntumoren-funktionsfaehig-haelt
Press release - 12/07/2023 Mast cells as a sensor: Enigmatic immune cells help to avoid harmful allergens The function of mast cells, which are part of the immune system, is still a mystery. Scientists at the German Cancer Research Center (DKFZ) have now shown in mice: mast cells function as a sensor that signals the animals to avoid antigens, including harmful allergens, and thereby protect themselves from health-threatening inflammatory reactions. The findings were published in the journal Nature.https://www.gesundheitsindustrie-bw.de/en/article/press-release/mastzellen-als-sensor-raetselhafte-immunzellen-helfen-schaedliche-allergene-zu-vermeiden
Press release - 28/08/2023 Innovative computational approach helps design proteins for cancer treatment The computational design of new proteins for biomedical or other applications involves long computing times on powerful servers. A joint team of researchers from the Max Planck Institute for Biology Tübingen and the University Hospital Tübingen has now developed and tested a new computational method to greatly speed up the necessary energy calculations. Their framework allows for a precise and efficient design of functional proteins.https://www.gesundheitsindustrie-bw.de/en/article/press-release/innovative-computational-approach-helps-design-proteins-cancer-treatment
Press release - 21/09/2023 Mutation-specific peptide vaccine against midline gliomas used in patients for the first time Tumor vaccines can help the body fight cancer. These vaccines alert the patient's immune system to proteins that are harbouring cancer-typical alterations. Physicians and cancer researchers from Heidelberg and Mannheim have now treated adult patients with advanced midline gliomas, difficult-to-treat brain tumors, with a peptide vaccine for the first time.https://www.gesundheitsindustrie-bw.de/en/article/press-release/mutation-specific-peptide-vaccine-against-midline-gliomas-used-patients-first-time